Search Results - "MACIAS, William L"

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis by Taylor, Peter C, Keystone, Edward C, van der Heijde, Désirée, Weinblatt, Michael E, del Carmen Morales, Liliana, Reyes Gonzaga, Jaime, Yakushin, Sergey, Ishii, Taeko, Emoto, Kahaku, Beattie, Scott, Arora, Vipin, Gaich, Carol, Rooney, Terence, Schlichting, Douglas, Macias, William L, de Bono, Stephanie, Tanaka, Yoshiya

“…In a phase 3 randomized trial of 1307 patients with rheumatoid arthritis receiving background methotrexate, the oral JAK1 and JAK2 inhibitor baricitinib showed…”
Get full text

Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations by McInnes, Iain B, Byers, Nicole L, Higgs, Richard E, Lee, Jonathan, Macias, William L, Na, Songqing, Ortmann, Robert A, Rocha, Guilherme, Rooney, Terence P, Wehrman, Thomas, Zhang, Xin, Zuckerman, Steven H, Taylor, Peter C

“…The in vitro pharmacology of baricitinib, upadacitinib, and tofacitinib was evaluated to understand differences among these JAK inhibitors (JAKis) at the…”
Get full text

JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial by Tuttle, Katherine R, Brosius, 3rd, Frank C, Adler, Sharon G, Kretzler, Matthias, Mehta, Ravindra L, Tumlin, James A, Tanaka, Yoshiya, Haneda, Masakazu, Liu, Jiajun, Silk, Maria E, Cardillo, Tracy E, Duffin, Kevin L, Haas, Joseph V, Macias, William L, Nunes, Fabio P, Janes, Jonathan M

“…Inflammation signaled by Janus kinases (JAKs) promotes progression of diabetic kidney disease (DKD). Baricitinib is an oral, reversible, selective inhibitor of…”
Get full text

Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients by Kim, Hanna, Brooks, Kristina M., Tang, Cheng Cai, Wakim, Paul, Blake, Mary, Brooks, Stephen R., Montealegre Sanchez, Gina A., de Jesus, Adriana A., Huang, Yan, Tsai, Wanxia Li, Gadina, Massimo, Prakash, Apurva, Janes, Jonathan Marcus, Zhang, Xin, Macias, William L., Kumar, Parag, Goldbach‐Mansky, Raphaela

“…Population pharmacokinetic (popPK) modeling was used to characterize the PK profile of the oral Janus kinase (JAK)1/JAK2 inhibitor, baricitinib, in 18 patients…”
Get full text

Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial by Nadel, Simon, FRCP, Goldstein, Brahm, MD, Williams, Mark D, MD, Dalton, Heidi, MD, Peters, Mark, PhD, Macias, William L, MD, Abd-Allah, Shamel A, MD, Levy, Howard, FRCP, Angle, Robinette, RN, Wang, Dazhe, PhD, Sundin, David P, PhD, Giroir, Brett, Dr

“…Summary Background Drotrecogin alfa (activated) (DrotAA) is used for the treatment of adults with severe sepsis who have a high risk of dying. A phase 1b…”
Get full text

Early changes in organ function predict eventual survival in severe sepsis by Levy, Mitchell M, Macias, William L, Vincent, Jean-Louis, Russell, James A, Silva, Eliezer, Trzaskoma, Benjamin, Williams, Mark D

“…OBJECTIVE:Early identification and treatment of severe sepsis can significantly reduce mortality rate. We hypothesized that a risk prediction model based on…”
Get full text

Recombinant Human Activated Protein C for the Postexposure Treatment of Ebola Hemorrhagic Fever by Hensley, Lisa E., Stevens, Edward L., Yan, S. Betty, Geisbert, Joan B., Macias, William L., Larsen, Tom, Daddario-DiCaprio, Kathleen M., Cassell, Gail H., Jahrling, Peter B., Geisbert, Thomas W.

“…Background. Infection of primates with Zaire ebolavirus (ZEBOV) leads to hypotension, coagulation disorders, and an impaired immune response and, in many ways,…”
Get full text

Interleukin-8 as a Stratification Tool for Interventional Trials Involving Pediatric Septic Shock by Wong, Hector R, Cvijanovich, Natalie, Wheeler, Derek S, Bigham, Michael T, Monaco, Marie, Odoms, Kelli, Macias, William L, Williams, Mark D

“…Interventional clinical trials involving children with septic shock would benefit from an efficient preenrollment stratification strategy. To test the…”
Get full text

Elevated Plasma Concentrations of IL-6 and Elevated APACHE II Score Predict Acute Kidney Injury in Patients with Severe Sepsis by Chawla, Lakhmir S, Seneff, Michael G, Nelson, David R, Williams, Mark, Levy, Howard, Kimmel, Paul L, Macias, William L

“…Acute kidney injury (AKI) is common in critically ill patients with severe sepsis (SS), and the predictors of AKI in this population have not been well…”
Get full text

Subcutaneous batoclimab in generalized myasthenia gravis: Results from a Phase 2a trial with an open‐label extension by Nowak, Richard J., Breiner, Ari, Bril, Vera, Allen, Jeffrey A., Khan, Shaida, Levine, Todd, Jacobs, Daniel H., Sahagian, Gregory, Siddiqi, Zaeem A., Xu, Jing, Macias, William L., Benatar, Michael, Adams, Laurence, Genge, Angela, Habib, Ali, Hinton, John L., Holmlund, Tomas H., Jacobs, Daniel H., Lange, Dale J., Nicolle, Michael W., Phan, Han C., Silvestri, Nicholas J., Small, George A., Yegiaian, Sharon

“…Objectives To assess the safety, tolerability, and key pharmacodynamic effects of subcutaneous batoclimab, a fully human anti‐neonatal Fc receptor monoclonal…”
Get full text

Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON-TIMI 38 Substudy by Riesmeyer, Jeffrey S., Salazar, Daniel E., Weerakkody, Govinda J., Ni, Lan, Wrishko, Rebecca E., Ernest II, C. Steven, Luo, Junxiang, Li, Ying G., Small, David S., Rohatagi, Shashank, Macias, William L.

“…In TRITON-TIMI 38, levels of the prasugrel active metabolite (pras-AM) were measured in a population pharmacokinetic substudy that characterized the intrinsic…”
Get full text

Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome by Shorr, Andrew F, Bernard, Gordon R, Dhainaut, Jean-Francois, Russell, James R, Macias, William L, Nelson, David R, Sundin, David P

“…Protein C, because of its central role in hemostasis, plays an integral role in the host response to infection. Protein C depletion, resulting from increased…”
Get full text

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment by Smolen, Josef S, Genovese, Mark C, Takeuchi, Tsutomu, Hyslop, David L, Macias, William L, Rooney, Terence, Chen, Lei, Dickson, Christina L, Riddle Camp, Jennifer, Cardillo, Tracy E, Ishii, Taeko, Winthrop, Kevin L

“…Baricitinib is an oral, once-daily selective Janus kinase (JAK1/JAK2) inhibitor for adults with moderately to severely active rheumatoid arthritis (RA). We…”
Get full text

Baricitinib in Patients with Refractory Rheumatoid Arthritis by Genovese, Mark C, Kremer, Joel, Zamani, Omid, Ludivico, Charles, Krogulec, Marek, Xie, Li, Beattie, Scott D, Koch, Alisa E, Cardillo, Tracy E, Rooney, Terence P, Macias, William L, de Bono, Stephanie, Schlichting, Douglas E, Smolen, Josef S

“…In this phase 3 study involving patients with an inadequate response to biologic disease-modifying antirheumatic drugs, baricitinib, an oral JAK1 and JAK2…”
Get full text

JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies by Sanchez, Gina A Montealegre, Reinhardt, Adam, Ramsey, Suzanne, Wittkowski, Helmut, Hashkes, Philip J, Berkun, Yackov, Schalm, Susanne, Murias, Sara, Dare, Jason A, Brown, Diane, Stone, Deborah L, Gao, Ling, Klausmeier, Thomas, Foell, Dirk, de Jesus, Adriana A, Chapelle, Dawn C, Kim, Hanna, Dill, Samantha, Colbert, Robert A, Failla, Laura, Kost, Bahar, O'Brien, Michelle, Reynolds, James C, Folio, Les R, Calvo, Katherine R, Paul, Scott M, Weir, Nargues, Brofferio, Alessandra, Soldatos, Ariane, Biancotto, Angelique, Cowen, Edward W, Digiovanna, John J, Gadina, Massimo, Lipton, Andrew J, Hadigan, Colleen, Holland, Steven M, Fontana, Joseph, Alawad, Ahmad S, Brown, Rebecca J, Rother, Kristina I, Heller, Theo, Brooks, Kristina M, Kumar, Parag, Brooks, Stephen R, Waldman, Meryl, Singh, Harsharan K, Nickeleit, Volker, Silk, Maria, Prakash, Apurva, Janes, Jonathan M, Ozen, Seza, Wakim, Paul G, Brogan, Paul A, Macias, William L, Goldbach-Mansky, Raphaela

“…Monogenic IFN-mediated autoinflammatory diseases present in infancy with systemic inflammation, an IFN response gene signature, inflammatory organ damage, and…”
Get full text

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate by Keystone, Edward C, Taylor, Peter C, Drescher, Edit, Schlichting, Douglas E, Beattie, Scott D, Berclaz, Pierre-Yves, Lee, Chin H, Fidelus-Gort, Rosanne K, Luchi, Monica E, Rooney, Terence P, Macias, William L, Genovese, Mark C

“…To investigate baricitinib (LY3009104, formerly INCB028050), a novel, oral inhibitor of JAK1/JAK2 in patients with moderate to severe rheumatoid arthritis (RA)…”
Get more information

Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes by MEGA, Jessica L, CLOSE, Sandra L, SABATINE, Marc S, WIVIOTT, Stephen D, LEI SHEN, HOCKETT, Richard D, BRANDT, John T, WALKER, Joseph R, ANTMAN, Elloitt M, MACIAS, William L, BRAUNWALD, Eugene

“…Both clopidogrel and prasugrel require biotransformation to active metabolites by cytochrome P450 (CYP) enzymes. Among persons treated with clopidogrel,…”
Get full text

Drotrecogin Alfa (Activated) in Adults with Septic Shock by Ranieri, V. Marco, Thompson, B. Taylor, Barie, Philip S, Dhainaut, Jean-François, Douglas, Ivor S, Finfer, Simon, Gårdlund, Bengt, Marshall, John C, Rhodes, Andrew, Artigas, Antonio, Payen, Didier, Tenhunen, Jyrki, Al-Khalidi, Hussein R, Thompson, Vivian, Janes, Jonathan, Macias, William L, Vangerow, Burkhard, Williams, Mark D

“…The efficacy of drotrecogin alpha (activated) (DrotAA) for sepsis has been controversial. In this trial, there was no significant difference in all-cause…”
Get full text

Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease by Kahaly, George J, Dolman, Peter J, Wolf, Jan, Giers, Bert C, Elflein, Heike M, Jain, Amy P, Srinivasan, Ashok, Hadjiiski, Lubomir, Jordan, David, Bradley, Elizabeth A, Stan, Marius N, Eckstein, Anja, Pitz, Susanne, Vorländer, Christian, Wester, Sara T, Nguyen, John, Tucker, Nancy, Sales-Sanz, Marco, Feldon, Steven E, Nelson, Christine C, Hardy, Isabelle, Abia-Serrano, Maravillas, Tedeschi, Philip, Janes, Jonathan M, Xu, Jing, Vue, Peter, Macias, William L, Douglas, Raymond S

“…Abstract Context Inhibition of the neonatal fragment crystallizable receptor (FcRn) reduces pathogenic thyrotropin receptor antibodies (TSH-R-Ab) that drive…”
Get full text

Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis by Genovese, Mark C, Kremer, Joel M, Kartman, Cynthia E, Schlichting, Douglas E, Xie, Li, Carmack, Tara, Pantojas, Carlos, Sanchez Burson, Juan, Tony, Hans-Peter, Macias, William L, Rooney, Terence P, Smolen, Josef S

“…Abstract Objective RA patients who have failed biologic DMARDs (bDMARDs) represent an unmet medical need. We evaluated the effects of baseline characteristics,…”
Get full text